Skip to main content

Advertisement

Table 1 A comparison of the frequency of mutations and copy number variations (CNV) in the components of the PI3K/AKT/mTOR pathway in AML, T-ALL, and B-ALL

From: Outlook on PI3K/AKT/mTOR inhibition in acute leukemia

Mutations
  Gene Description AML SNP AML CNV T -ALL SNP B -ALL SNP
PI3K/AKT/mTOR PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha 0% (228) 0.5% (188) loss 0% (20) 0% (9)
  PIK3CB phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta 0% (228) 0.5% (188) loss 0% (20) 0% (9)
  PIK3CD phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta 0% (228) 2.71% (188) gain, 0.5% (188) loss 0% (28) 0% (9)
  PIK3CG phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma 0% (228) 9% (188) loss 0% (28) 0% (9)
  PTEN phosphatase and tensin homolog 0.48% (417) 1.1% (188) gain, 0.5% (188) loss 15.66% (862) 0% (81)
  AKT1 v-akt murine thymoma viral oncogene homolog 1 0% (571) 1.1%, (188) gain, 2.7% (188) loss 1.9% (203) 0% (76)
  AKT2 v-akt murine thymoma viral oncogene homolog 2 0% (228) 4.8% (188) gain 0% (22) 0% (9)
  AKT3 v-akt murine thymoma viral oncogene homolog 3 0% (228) 2.1% (188) gain, 0.5% (188) loss 0% (20) 0% (9)
  mTOR mechanistic target of rapamycin (serine/threonine kinase) 0.44% (228) 2.71% (188) gain, 0.5% (188) loss 0% (20) 0% (9)
  PI3KR1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 0% (328) 0.5% (188) gain, 2.71% (188) loss 0.56% (178) 0% (58)
Receptors TLR4 toll-like receptor 4 0.44% (228) 3.7% (188) gain, 0.5% (188) loss 0% (20) 0% (9)
  NRAS neuroblastoma ras viral oncogene 10.69% (4351) 1.1% (188) gain, 0.5% (188) loss 10.36% (502) 0% (818)
  KRAS phosphatase and tensin homolog 4.1% (2339) 1.6% (188) loss 1.75% (456) 10,36% (772)
  EGFR epidermal growth factor receptor 0.44% (229) 6.9% (188) loss 13.79% (29) 0% (9)
  FLT3 fms-related tyrosine kinase 3 23.75% (62135) 1.6% (188) gain, 1.1% (188) loss 4,59% (740) 4,04% (792)
  EPHA3 EPH receptor A3 0.44% (229) 2.7% (188) loss 0% (20) 0% (9)
  ERBB4 v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4 0% (228) 0.5% (188) gain 0% (20) 0% (9)
  PDGFRA platelet-derived growth factor receptor, alpha polypeptide 1.02% (394) 2.1% (188) gain 11.54% (26) 0% (9)
  EPHB6 EPH receptor B6 0% (228) 0.5% (188) gain, 10.6% (188) loss 0% (20) 0% (9)
  FGFR2 fibroblast growth factor receptor 2 0% (228) 1.1% (188) gain 8.33% (24) 0% (9)
  KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 8.82% (5895) 2.1% (188) gain 0% (1) 0% (10)
  FGFR3 fibroblast growth factor receptor 3 0% (228) 1.6% (188) gain, 2.1% (188) loss 23.33% (30) 0% (9)
  1. Frequency and cohort size are indicated. Mutational frequencies and CNVs were obtained from COSMIC repository [48] v69.
  2. Listed are the major PI3K/AKT/mTOR components including gene symbols, description of the genes, and frequency of mutation in each disease and CNV in AML.